Brief: Study Progress Triggers $3 Mln Payment For IRLAB

IRLAB Therapeutics AB

26/02/2026 14:20

Feb 26 (Reuters) - IRLAB Therapeutics AB IRLABa.ST:

DOSES FIRST PATIENT IN PHASE IB STUDY WITH IRL757

USD 3 MILLION MILESTONE PAYMENT TRIGGERED FOR IRLAB

Source text: ID:nMFN9mQ5jJ

Further company coverage: [IRLABa.ST]

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))